Search
Iloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.
Posizolid
go.drugbank.com/drugs/DB04850InvestigationalIn July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though … Posizolid (AZD2563) is an oxazolidinone antibiotic.
Ventilator Associated Bacterial Pneumonia (VABP) caused by Acinetobacter Baumannii-calcoaceticus Complex
go.drugbank.com/conditions/DBCOND0159091Synonyms: Ventilator Associated Bacterial Pneumonia (VABP) caused by Acinetobacter Baumannii-calcoaceticus ComplexCholecystokinin
go.drugbank.com/drugs/DB08862ApprovedInvestigationalWithdrawnRecent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity … Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.
Merbromin
go.drugbank.com/drugs/DB13392InvestigationalIt is an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market
Products: BERKOMER SOLUSYON, 50 MLBG-777
go.drugbank.com/drugs/DB05839ExperimentalBG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued … a 68% reduction in the risk of death were observed.
Categories: Skin and Mucous Membrane AgentsSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalSamidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction. … [A235623, A235638, L34359] Although antipsychotic-induced weight gain is incompletely understood, it is thought that the opioid system plays a key role in feeding and metabolism, such that opioid antagonism
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722] … Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures.
Ociperlimab
go.drugbank.com/drugs/DB18947InvestigationalOciperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage
Synonyms: Immunoglobulin g1-kappa, anti-(homo sapiens tigit (t-cell immunoreceptor with ig domain and itim, v-set ig member 9, vsig9, v-set and transmembrane member 3, vstm3)), humanized monoclonal antibody (ociperlimab